{
    "nctId": "NCT00436709",
    "briefTitle": "Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer",
    "officialTitle": "A Pilot Study of Bevacizumab With Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Dose Dense Nanoparticle Albumin Bound Paclitaxel for the Treatment of Early Stage Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 75,
    "primaryOutcomeMeasure": "Safety",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed invasive breast cancer meeting the following criteria:\n\n  * Early-stage disease\n\n    * No stage IV disease\n  * More than one synchronous primary breast tumor\n  * Lymph node positive OR high-risk lymph node negative\n* Candidate for treatment with anthracycline- and taxane-based chemotherapy in the adjuvant setting\n\n  * Must begin therapy within 84 days after the final required surgical procedure\n* HER2/neu-negative breast cancer, defined as an immunohistochemistry (IHC) score of 0, 1+ or 2+ and fluorescent in situ hybridization (FISH) not amplified\n* No CNS disease (e.g., primary brain tumor or brain metastasis)\n* Hormone receptor status known\n\nPATIENT CHARACTERISTICS:\n\n* Male or female\n* Pre- or post-menopausal\n* ECOG performance status 0-1\n* Absolute neutrophil count \u2265 1,000/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Bilirubin normal\n* AST or ALT \u2264 2.5 times upper limit of normal\n* Creatinine normal OR creatinine clearance \u2265 60 mL/min\n* Urine protein:creatinine ratio \u2264 1.0\n* PT and PTT normal\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 6 months after completion of study therapy\n* LVEF normal by MUGA scan at baseline\n* No significant bleeding within the past 6 months\n* No uncontrolled underlying bleeding diathesis\n* No nonmalignant systemic disease (e.g., cardiovascular, renal, or hepatic) that would preclude study therapy, including any of the following conditions:\n\n  * Blood pressure \\> 150/100 mm Hg\n  * Unstable angina\n  * New York Heart Association class II -IV congestive heart failure\n  * Myocardial infarction or stroke within the past 12 months\n  * Clinically significant peripheral vascular disease\n* No seizures not controlled with standard medical therapy\n* No history of stroke\n* No known allergy or hypersensitivity to study drugs (prior hypersensitivity to paclitaxel allowed)\n* No significant traumatic injury within the past 28 days\n* No serious nonhealing wound, ulcer, or bone fracture\n* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months\n* No active gastroduodenal ulcer\n* No uncontrolled intercurrent illness, including psychiatric illness or social situation that would limit compliance with study requirements\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Prior therapy for an ipsilateral or contralateral breast cancer primary allowed provided the following criteria are met:\n\n  * No prior anthracycline therapy\n  * Prior hormonal therapy for this previous breast cancer is allowed, but must be stopped during study therapy\n  * At least 1 year since prior taxane therapy\n* More than 28 days since prior and no concurrent major surgery or open biopsy\n\n  * Anticipated reconstructive surgery (e.g., tissue expander exchange) is allowed during the course of the study (bevacizumab will be held during that time as per protocol guidelines)\n* More than 7 days since prior minor surgery, including fine-needle aspiration or core biopsy\n\n  * At least 24 hours since prior indwelling catheter placement\n* No prior bevacizumab or other KDR inhibitors (e.g., VEGF Trap, semaxanib, SU6668, vandetanib, vatalanib, AEE788, or IMC-1CII)\n* No concurrent full-dose anticoagulation therapy\n* No concurrent hormonal therapy as chemoprevention\n* Concurrent participation in adjuvant hormone therapy or correlative or companion (e.g., bisphosphonate clinic) studies allowed\n* No other concurrent anticancer therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}